ONI, is stepping into the growing field of lipid nanoparticle research. LNPs are crucial for delivering therapies like mRNA vaccines and gene therapies, and ONI’s move highlights the importance of better understanding how these delivery systems work.
Lipid nanoparticles are tiny, protective carriers that help deliver drugs or genetic material to specific cells in the body. They’ve become essential in the development of mRNA vaccines, such as those for COVID-19, and are gaining attention in personalized medicine. ONI is bringing its Nanoimager technology—used for high-resolution imaging at the nanoscale—into the LNP space to offer a clearer view of how these particles behave, how stable they are, and how effectively they deliver their cargo to target cells.
Dr. Jason Jell, Vice President of Marketing at ONI, explained, “We’ve been using our technology to study extracellular vesicles, so moving into LNPs felt like a natural step. LNPs are becoming key in vaccines and gene therapies, but there’s still a lot to learn about how to make them more efficient. Our tools can help researchers see what’s happening at the nanoscale and tackle some of the challenges with delivery and stability.”
To help researchers better understand the potential of its Nanoimager technology in LNP research, ONI is hosting a live virtual demo and a webinar titled “Why SMLM for LNP Research?” These events will explore how super-resolution microscopy can advance studies of lipid nanoparticles.
As the use of LNPs continues to grow, ONI’s involvement could help address some of the challenges that researchers and developers face in making these delivery systems more reliable and effective.